As of Oct 26, 2026: Corcept Therapeutics (CORT) has a PDUFA date for relacorilant on Dec 17, 2026, in 52 days. Its Quality Score is 9. Scores as of 9:21 PM ET, 15 minutes behind.

CORT FDA decision on Relacorilant

Corcept Therapeutics · PDUFA date

PDUFA dateDec 17in 52 days Quality Score9Average

Cash runway–brings in cash

What the company said

“Relacorilant for patients with Cushing’s syndrome – New Drug Application for relacorilant resubmitted with a Prescription Drug User Fee Act (PDUFA) date of December 17, 2026”

PDUFA date, Dec 17, 2026. As Corcept Therapeutics stated in its 8-K of Jul 29, 2026 (the filing).

A PDUFA date is the day the FDA has said it aims to decide on a drug. The FDA can decide earlier, or extend its review, often by three months.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Get an alert before CORT's FDA date

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

How CORT's stock moved on its past FDA days, for Pro members. Pro members also see whether its cash lasts past Dec 17, and the members' FDA calendar with filters and optional alerts.

More on CORT and the FDA calendar

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

The FDA calendar.